Brokers Issue Forecasts for Fate Therapeutics Inc's FY2019 Earnings (NASDAQ:FATE)

  • Summary:


    Fate Therapeutics Inc (NASDAQ:FATE) – Equities research analysts at Wedbush lifted their FY2019 earnings per share estimates for Fate Therapeutics in a research note issued on Thursday, November 7th, according to Zacks Investment Research. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($1.43) per share for the year, up from their prior forecast of ($1.45). Wedbush currently has a “Outperform” rating and a $26.00 price objective on the stock. Wedbush also issued estimates for Fate Therapeutics’ Q4 2019 earnings at ($0.37) EPS, Q1 2020 earnings at ($0.37) EPS, Q2 2020 earnings at ($0.33) EPS, Q3 2020 earnings at ($0.39) EPS, FY2020 earnings at ($1.48) EPS, Q1 2021 earnings at ($0.38) EPS, Q2 2021 earnings at ($0.39) EPS, Q3 2021 ea ...



    Read Full News:

Log in to reply